Tripeptide/Hexapeptide System Effective After Laser Resurfacing

This article originally appeared here.
Share this content:
Tripeptide/Hexapeptide System Effective After Laser Resurfacing
Tripeptide/Hexapeptide System Effective After Laser Resurfacing

THURSDAY, April 13, 2017 (HealthDay News) -- Use of a tripeptide/hexapeptide topical system following fractionated CO2 laser resurfacing is effective and well tolerated, according to a study published online March 31 in the Journal of Cosmetic Dermatology.

Monique J. Vanaman Wilson, M.D., from Goldman Butterwick Groff Fabi & Wu Cosmetic Laser Dermatology in San Diego, and colleagues conducted a randomized study involving 15 women aged 45 to 70 years undergoing laser resurfacing of the face. From three weeks before until 12 weeks after the procedure, the participants were randomized to use either the tripeptide/hexapeptide system (10 women) or a bland dimethicone-based ointment and petrolatum-based cream (five women). Data were analyzed from 14 women.

The researchers found that blinded investigator-rated healing was better for the tripeptide/hexapeptide system, with the difference reaching statistical significance at day seven. During the first post-procedure week, there was less erythema and exudation in the tripeptide/hexapeptide group, reaching statistical significance on day three. Subjects using the tripeptide/hexapeptide system reported less tenderness and burning/stinging on days one through 14, reaching significance on day three. Subjects using the tripeptide/hexapeptide system reported higher satisfaction on day 84, and they were more likely to recommend the treatment to others.

"Postresurfacing use of a tripeptide/hexapeptide system proved effective and well tolerated," the authors write. "Subject satisfaction was greater among those using this system, which may indicate an improved patient experience following laser resurfacing."

The study was funded by Alastin Skincare.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »